Abstract
Prostaglandins serve as the connecting link between inflammation and cancer. mPGES1, the downstream enzyme in the prostaglandin pathway is considered a better target than COX-2 against the progression of cancer due to the cardiovascular and other complications associated with the inhibition of the latter. Despite the discovery of several compounds that inhibit mPGES1 none could enter the market as drugs because of the problems concerning specificity and unacceptable pharmacokinetic properties. Expression of mPGES1 is inducible in conditions of inflammation and hypoxia and its expression is regulated by a number of transcriptional factors. Targeting these transcription factors could be an alternative approach in the drug discovery process. In this review, the characteristics of the transcription factors, their ability to bind to the promoter of mPGES1 gene and the inhibitors against them have been discussed. The Structure Activity Relationship of the reported inhibitors is highlighted. Finally, practical challenges to further the drug development and future research directions are discussed. These novel compounds that are inhibitors of the major transcription factors are promising candidates for further development as inhibitors of mPGES1.
Keywords: Cancer, inflammation, inhibitors, prostaglandin E synthase, transcription factors.
Current Drug Targets
Title:Transcriptional Regulation of mPGES1 in Cancer: An Alternative Approach to Drug Discovery?
Volume: 18 Issue: 1
Author(s): Meera Ramanan and Mukesh Doble
Affiliation:
Keywords: Cancer, inflammation, inhibitors, prostaglandin E synthase, transcription factors.
Abstract: Prostaglandins serve as the connecting link between inflammation and cancer. mPGES1, the downstream enzyme in the prostaglandin pathway is considered a better target than COX-2 against the progression of cancer due to the cardiovascular and other complications associated with the inhibition of the latter. Despite the discovery of several compounds that inhibit mPGES1 none could enter the market as drugs because of the problems concerning specificity and unacceptable pharmacokinetic properties. Expression of mPGES1 is inducible in conditions of inflammation and hypoxia and its expression is regulated by a number of transcriptional factors. Targeting these transcription factors could be an alternative approach in the drug discovery process. In this review, the characteristics of the transcription factors, their ability to bind to the promoter of mPGES1 gene and the inhibitors against them have been discussed. The Structure Activity Relationship of the reported inhibitors is highlighted. Finally, practical challenges to further the drug development and future research directions are discussed. These novel compounds that are inhibitors of the major transcription factors are promising candidates for further development as inhibitors of mPGES1.
Export Options
About this article
Cite this article as:
Ramanan Meera and Doble Mukesh, Transcriptional Regulation of mPGES1 in Cancer: An Alternative Approach to Drug Discovery?, Current Drug Targets 2017; 18 (1) . https://dx.doi.org/10.2174/1389450117666160826093137
DOI https://dx.doi.org/10.2174/1389450117666160826093137 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Secretory Leukocyte Protease Inhibitor: More than Just A Protease Inhibitor
Current Immunology Reviews (Discontinued) Current Pharmacological Approaches to Prevent and Treat Post- Menopausal Osteoporosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) UBE2L6 is Involved in Cisplatin Resistance by Regulating the Transcription of ABCB6
Anti-Cancer Agents in Medicinal Chemistry Psychosocial Stress, Emotions and Cytokine-Related Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Pathogenetic Correction of the Enteric Insufficiency Syndrome in Patients with Advanced Peritonitis
Reviews on Recent Clinical Trials Exploration of Medicinal Plants as Sources of Novel Anticandidal Drugs
Current Topics in Medicinal Chemistry New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets Understanding the Molecular Mechanisms of Betel miRNAs on Human Health
MicroRNA Interactions of the Aryl Hydrocarbon Receptor with Inflammatory Mediators:Beyond CYP1A Regulation
Current Drug Metabolism Genistein Aglycone: A Dual Mode of Action Anti-Osteoporotic Soy Isoflavone Rebalancing Bone Turnover Towards Bone Formation
Current Medicinal Chemistry Review: Circulating microRNAs in Predicting the Prognosis of Gastrointestinal Cancers
Current Biomarkers (Discontinued) Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches
Current Medicinal Chemistry Immunological and Metabolic Alterations in Esophageal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets The Effect of GLUT1 on the Survival Rate and Immune Cell Infiltration of Lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta and Bioinformatics Analysis
Anti-Cancer Agents in Medicinal Chemistry Adhesion Dependent Signalling in the Tumour Microenvironment: The Future of Drug Targetting
Current Pharmaceutical Design Has Selenium a Chemopreventive Effect on Hepatocellular Carcinoma?
Mini-Reviews in Medicinal Chemistry Combinations Against Combinations: Associations of Anti-HIV 1 Reverse Transcriptase Drugs Challenged by Constellations of Drug Resistance Mutations
Current Drug Metabolism Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications
Current Drug Targets Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence
Current Pharmaceutical Design High Expression of miR-206 Predicts Adverse Outcomes: A Potential Therapeutic Target for Esophageal Cancer
Combinatorial Chemistry & High Throughput Screening